Ocimum Biosolutions ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009

Ocimum Biosolutions, a leading integrated genomics company, today announced that it ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009, a ranking of the 500 fastest growing technology companies in Asia Pacific. Rankings are based on percentage revenue growth over three years. In addition to ranking on Deloitte’s Technology Fast 500, Ocimum ranked fourth on the Technology Fast 50 India Program, which is a ranking of the 50 fastest growing technology firms in India.

Earlier this year the INC magazine listed Ocimum as one the fastest growing companies in North America. Ocimum offers a global genomics infrastructure that includes GLP compliant labs, gold standard databases, biorepository and analytics on hosted data management platform. The company is building a state-of-the-art facility at their corporate headquarters in Hyderabad which will mirror the GLP and CLIA facilities available in Gaithersburg.

Anu Acharya, CEO, Ocimum Biosolutions, said that. “We have always let customers’ needs drive our priorities. As the pharma and biotech industry evolves, the need for a global genomics infrastructure is desired. Ocimum has all the elements and we have created an infrastructure where we take on complete accountability to create consistent data for our customers.”

She added, “We are indebted to our growing list of global customers, who have trusted us over the years, referred us as partners in their R&D efforts. This has helped us continuously expand our portfolio and offer unique range of integrated solutions.”

“Being one of the 500 fastest growing technology companies in Asia Pacific is an impressive accomplishment. We commend Ocimum Biosolutions for making the Deloitte Technology Fast 500 Asia Pacific with a phenomenal 663% growth rate over five years,” said Yoshitaka Asaeda, partner in charge of Deloitte’s Technology Fast 500 Asia Pacific program.

Source:

Ocimum Biosolutions

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer